Pudong, Shandong, China The venture was found in Asia in China. The main office of represented VC is situated in the Pudong.
The fund has exact preference in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight ZAI Lab, Antengene Corporation, Asieris Pharmaceuticals. Among the most successful fund investment fields, there are Biopharma, Pharmaceutical. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.
The fund is constantly included in 2-6 investment rounds annually. The increased amount of exits for fund were in 2017. Deals in the range of 10 - 50 millions dollars are the general things for fund. This TF Capital works on 22 percentage points less the average amount of lead investments comparing to the other organizations. Considering the real fund results, this VC is 13 percentage points less often commits exit comparing to other organizations. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the TF Capital, startups are often financed by Qiming Venture Partners, Sequoia Capital China, Kleiner Perkins. The meaningful sponsors for the fund in investment in the same round are Qiming Venture Partners, Sinopharm Capital, Sequoia Capital China. In the next rounds fund is usually obtained by Sequoia Capital China, OrbiMed, Lapam Capital.
Besides them, we counted 1 critical employee of this fund in our database.
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Allorion Therapeutics | $40M | 24 Nov 2021 | Natick, Massachusetts, United States | ||
Abogen Biosciences | $92M | 08 Apr 2021 | Gusu District, Jiangsu, China | ||
| $100M | 08 Dec 2020 | Shanghai, China | |||
Hanyu Medical | $77M | 13 Aug 2020 | China, Shanghai | ||
EOC Pharma Group | $77M | 02 Dec 2019 | China, Shanghai | ||
Tisenc | $12M | 06 Sep 2019 | Futian District, Guangdong Province, China | ||
GeneQuantum Healthcare | $15M | 07 May 2019 | China, Beijing | ||
Abbisko Therapeutics | $42M | 21 Mar 2019 | China, Shanghai | ||
Antengene Corporation | $120M | 02 Jan 2019 | China, Shanghai |
– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.
– Regor Therapeutics announced the successful completion of $90m Series B financing.
– The round was led by Lilly Asia Ventures and included participation from Loyal Valley Capital, Lanting Capital, TF Capital and Vertex Ventures China.
– Regor Therapeutics was established with initial series A strategic investment from Qilu Pharmaceutical Group, a well-known Chinese pharmaceutical company.
– Regor Therapeutics is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, seamlessly integrating structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development.
– Regor has assembled a world-class scientific team and demonstrated high efficiency in producing best- and first-in-class molecules.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Top 20 VC funds in Eastern Asia that took part in the most Early Stage funding rounds in Wellness/Personal Health industry over the recent yearsSign up and get access to full fund profile and advanced analysis.
Full
teamIndustries
heatmapStages
heatmapGeorgaphy
breakdownCoinvestorsPortfolio
analysisPerformance
indexesLatest
highlights
Unlock all data 
